Tiger Brokers

Pfizer Gets Expanded European OK for Hympavzi Hemophilia Drug

Dow Jones
May 13

By Colin Kellaher

Pfizer has won expanded European Commission approval of its Hympavzi hemophilia drug for two patient populations.

Pfizer on Wednesday said the green light covers patients ages 12 and older weighing at least 35 kilograms with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors.

The New York drugmaker said inhibitors limit treatment options for people living with hemophilia and are associated with an increased risk of uncontrolled bleeding.

Pfizer said Hympavzi is now the only once-weekly subcutaneous treatment approved in the European Union for people living with hemophilia A or B with or without inhibitors.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 13, 2026 06:56 ET (10:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10